The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

A Look At Cooper Companies (COO) Valuation As Shares Face Recent Price Pressure - Yahoo Finance

AI-generated analysis

πŸ“‰ Cooper Companies (COO) shares have faced recent downward pressure, declining 9% over the past month and approximately 17% over the last three months.

πŸ’΅ The company closed at US$69.66 with a total market capitalization of around US$13.7 billion.

🏒 Cooper Companies operates through two primary business segments: CooperVision (contact lenses) and CooperSurgical (medical devices, fertility products, and contraceptives).

πŸ’° Reported annual revenue reached US$4.15 billion with net income of US$401.4 million, reflecting 5.1% revenue growth and 16.6% net income growth.

🌍 Revenue is geographically split between US$2.75 billion from the United States and US$2.42 billion from Europe, excluding segment adjustments.

πŸ“ˆ Analysts estimate a fair value of US$91.80 per share, suggesting the current stock is potentially undervalued relative to their forecasts.

🧠 Future free cash flow is expected to increase significantly as capital expenditure cycles wind down, with management guiding approximately US$2 billion over the next three years.

⚠️ The valuation relies on successful execution of capacity expansion at MyDAY and sustained demand for fertility and PARAGARD products.

πŸ“Š Current P/E ratio of 33.9x is notably higher than peer average of 22.2x and US medical equipment sector average of 26.7x.

πŸ› οΈ Improved cash generation could benefit shareholders through debt reduction and increased share repurchases under management's guidance.

βš–οΈ Investors face a choice between believing the market misprices future growth or acknowledging that high valuation multiples require flawless execution.

πŸ” Simply Wall St analysis identifies 3 key rewards for holding Cooper Companies despite mixed signals regarding price pressure.

πŸ’‘ The article suggests diversifying into other opportunities such as dividend fortresses, high-quality undervalued stocks, and resilient low-risk portfolios.

βš–οΈ This content is provided by Simply Wall St and does not constitute financial advice or a recommendation to buy or sell the stock.

Bullish Signals
  • Cooper Companies reported net income growth of 16.6% on an annual revenue of US$4.15b, demonstrating strong earnings momentum.
  • Analyst forecasts project approximately $2 billion in free cash flow over the next three years as capital expenditures wind down and MyDAY capacity ramps up.
  • The company maintains a discount to its fair value estimate of $91.80, suggesting significant upside potential if current valuations correct.
  • CooperVision generated US$2.79b in revenue focusing on contact lenses for myopia, presbyopia, and astigmatism, while CooperSurgical contributed US$1.36b with exposure to fertility products and contraception.
  • The company has annual revenue growth of 5.1%, indicating sustained demand across its healthcare segments.
Risk Factors
  • The stock has faced significant downward price pressure, declining approximately 17% over the past three months and entering bear market territory relative to its recent highs.
  • Despite reported growth, the current P/E ratio of 33.9x sits well above peers at 22.2x and the US medical equipment average at 26.7x, leaving little room for error if future growth underdelivers.
  • The positive valuation narrative hinges critically on MyDAY's capacity ramp converting efficiently into sustained sales, a risk that could easily derail expected upside.
  • Demand for fertility products and PARAGARD could weaken further, which would directly threaten the revenue stream from CooperSurgical (CSI).
  • Analyst forecasts rely on an almost perfect alignment of growth, profitability, and share count shrinking, suggesting high sensitivity to any single metric missing expectations.
  • The company's current price of US$69.66 is significantly below the fair value estimate of $91.80, implying the market may have already priced in risks not yet reflected in analyst targets.
Full Analysis
Cooper Companies (COO) has experienced recent downward pressure on its share price, with declines of 0.9% over the past day, 2.6% over the week, approximately 9% over the month, and about 17% over the last three months. The company closed at US$69.66, representing a market value of roughly US$13.7 billion. Cooper Companies is structured around two primary business segments with distinct healthcare spending profiles: CooperVision (CVI) and CooperSurgical (CSI). CooperVision generated revenue of US$2.79 billion, primarily focused on contact lenses for conditions including astigmatism, presbyopia, and myopia, while CooperSurgical contributed US$1.36 billion tied to women’s and family health products such as fertility services, medical devices, contraception, and cryostorage. Financially, the company reported annual revenue of US$4.15 billion with a net income of US$401.4 million, marking a 5.1% increase in annual revenue and a 16.6% growth in net income. Regional breakdowns show US$2.75 billion in revenue from the United States and US$2.42 billion from Europe, alongside a segment adjustment of US$1.02 billion noted for investor comparisons. Long-term shareholder returns indicate a challenging outlook, with a 3-year total shareholder return of 25.1% and a 5-year total shareholder return of 28.7%, contrasting with the recent fading momentum seen in the 30-day and 3-month trading periods. Analyst narratives suggest Cooper Companies could be undervalued with a fair value target of US$91.80, significantly higher than the current close of US$69.66. This valuation gap is predicated on forecasts for improved earnings, margins, share buybacks, and rising free cash flow expected to reach approximately US$2 billion over the next three years as capital expenditure cycles wind down following the ramp-up of MyDAY capacity. However, this positive narrative relies heavily on assumptions such as efficient conversion of MyDAY’s production capacity into sustained sales and stable demand for fertility products and PARAGARD. Despite the potential upside, valuation metrics present mixed signals that warrant caution. Cooper Companies currently trades at a price-to-earnings (P/E) ratio of 33.9x, which is substantially above its peers at 22.2x, the US medical equipment sector average of 26.7x, and a fair P/E ratio of 28.2x. This premium reflects high expectations for future earnings growth, meaning there may be less room for error if actual performance does not meet projections. Investors are encouraged to consider whether the market has already priced in this future growth or if the stock is mispriced given these elevated multiples and potential risks related to demand weakening in key segments.